Fred Henry Rodriguez

Fred Henry Rodriguez

Auto-generated profile, based on publicly available information

Fred Henry Rodriguez

Emory University School of Medicine

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2012 in Congenital Heart Disease
Verified
Journal Article
Closed access
PDF file
FRFred H. Rodriguez
Fred H. Rodriguez
DMDouglas S. Moodie
Douglas S. Moodie
DPDhaval R. Parekh
Dhaval R. Parekh
WFWayne J. Franklin
Wayne J. Franklin
DMDavid L.S. Morales
David L.S. Morales
JRJoseph W. Rossano
Joseph W. Rossano
Background Heart failure (HF) accounts for >3 million hospital admissions annually in adults with acquired cardiovascular disease, but there are limited data on HF admissions in adults with congenital heart disease (ACHD). The purpose of this study was to test the hypotheses that HF admissions are common in ACHD and associated with significant morbidity and mortality. Methods The 2007 Nationwide Inpatient Sample was used to assess national prevalence, morbidities, and risk factors for mortality during hospitalizations among ACHD with HF. Results Of the 84 308 (95% CI 71 345–97 272) ACHD admissions in the United States in 2007, 17 193 (95% CI 14 157–20 229) had a diagnosis of HF (20%). ACHD with HF was associated with an increased risk of death compared to ACHD without HF (OR 3.3, 95% CI 2.6–4.1). On multivariable analysis independent risk factors for mortality included nonoperative intubation (OR 6.1, 95% CI 3.3–11.4), sepsis (OR 4.3, 95% CI 2.4–7.4), and acute myocardial infarction (OR 3.2, 95% CI 1.8–5.7). Cardiac defects associated with an increased risk of mortality included ventricular septal defects (VSDs) (OR 1.8, 95% CI 1.0–3.4). Conclusions In this large population-based study, HF-related hospitalizations were common in ACHD and associated with an increased risk of death compared to non-HF admissions. The risk of mortality is increased with the diagnoses of VSDs and the presence of specific comorbidities such as respiratory failure and sepsis.

17 August 2014 in Congenital Heart Disease
Verified
Journal Article
Open access
PDF file
RERobert W. Elder
Robert W. Elder
NMNancy M. McCabe
Nancy M. McCabe
EVEmir Veledar
Emir Veledar
BKBrian E. Kogon
Brian E. Kogon
MJMaan Jokhadar
Maan Jokhadar
WBWendy M. Book
Wendy M. Book
Objective Risk factors for major adverse events late after Fontan palliation are unknown. Prior studies have suggested ventricular function and morphology as important risk factors. The aim of this study is to (1) characterize the late major adverse event profile in adult Fontan patients and (2) identify additional risk factors that may contribute to adverse outcomes. Design and Setting A retrospective review of all adult patients >15 years post‐Fontan seen at a tertiary academic center was conducted. Clinical, laboratory, cardiac data, and abdominal imaging were collected via chart review. Major adverse events (death, cardiac transplantation, or listing) were identified, and timing of events was plotted using Kaplan–Meier methods. Univariate and multivariate logistic regression was used to determine independent predictors of late‐term events. Results A total of 123 adult Fontan patients were identified (mean time post‐Fontan 22.4 years [±4.4]). Major adverse events occurred in 19/123 patients (15%). In this 15‐year survivor cohort, transplant‐free survival rates were 94.6%, 82.9%, and 59.8% at 20, 25, and 30 years postoperation, respectively. Modes of death were Fontan failure with preserved function (4), congestive heart failure with decreased function (2), sudden death (2), thromboembolic event (1), post‐Fontan conversion (2), and posttransplant (2). No differences in adverse outcomes were found based on morphology of the systemic ventricle, Fontan type, or systolic ventricular function. On the other hand, features of portal hypertension (OR 19.0, CI 4.7–77.3, P < .0001), presence of a pacemaker (OR 13.4, CI 2.6–69.8, P = .002), and systemic oxygen desaturation (OR 0.86, CI 0.75–0.98, P = .02) were risk factors for major adverse events in the multivariate analysis. Conclusions In adult Fontan patients surviving >15 years post‐Fontan, portal hypertension, oxygen desaturation, and need for pacemaker were predictive of adverse events. Traditional measures may not predict late‐term outcomes in adult survivors; further study of the liver's role in late outcomes is warranted.

20 December 2017 in Congenital Heart Disease
Verified
Journal Article
Open access
PDF file
FRFred H. Rodriguez
Fred H. Rodriguez
GEGeorges Ephrem
Georges Ephrem
JGJennifer F. Gerardin
Jennifer F. Gerardin
CRCheryl Raskind-Hood
Cheryl Raskind-Hood
CHCarol Hogue
Carol Hogue
WBWendy Book
Wendy Book
Objective Although the ICD‐9‐CM code 745.5 is widely used to indicate the presence of a secundum atrial septal defect (ASD), it is also used for patent foramen ovale (PFO) which is a normal variant and for “rule‐out” congenital heart disease (CHD). The ICD‐10‐CM code Q21.1 perpetuates this issue. The objective of this study was to assess whether code 745.5 in isolation or in combination with unspecified CHD codes 746.9 or 746.89 miscodes for CHD, and if true CHD positives decrease with age. Design Echocardiograms of patients with an ICD‐9‐CM code of 745.5 in isolation or in combination with unspecified CHD codes 746.9 or 746.89 were reviewed to validate the true incidence of an ASD. This observational, cross‐sectional record review included patients between 11 and 64 years of age. Results Medical charts and echocardiograms of 190 patients (47.9% males) were reviewed. The number of falsely coded patients with 745.5 (no ASD) was high (76.3%). Forty‐five (23.7%) patients had a true ASD. Among the 145 patients without an ASD, 100 (52.6%) were classified as having a PFO, 37 (19.5%) had a normal non‐CHD echocardiogram, and 8 (4.2%) had some other CHD anomaly. The likelihood that 745.5 coded for a true ASD was higher in children aged 11‐20 (64.3%) than adults aged 21‐64 years (20.6%). Conclusions This validation study demonstrates that 745.5 performed poorly across all ages. As 745.5 is widely used in population‐level investigations and ICD‐10‐CM perpetuates the problem, future analyses utilizing CHD codes should consider separate analysis of those identified only through code 745.5.

28 January 2021 in Blood
Verified
Journal Article
Open access
PDF file
FSFrancesco Saettini
Francesco Saettini
Cecilia Poli-HarloweCecilia Poli-Harlowe
Cecilia Poli-Harlowe
JVJaime Vengoechea
Jaime Vengoechea
SBSonia Bonanomi
Sonia Bonanomi
JOJulio C. Orellana
Julio C. Orellana
ABAndrea Biondi
Andrea Biondi
Agammaglobulinemia is the most profound primary antibody deficiency that can occur due to an early termination of B-cell development. We here investigated 3 novel patients, including the first known adult, from unrelated families with agammaglobulinemia, recurrent infections, and hypertrophic cardiomyopathy (HCM). Two of them also presented with intermittent or severe chronic neutropenia. We identified homozygous or compound-heterozygous variants in the gene for folliculin interacting protein 1 (FNIP1), leading to loss of the FNIP1 protein. B-cell metabolism, including mitochondrial numbers and activity and phosphatidylinositol 3-kinase/AKT pathway, was impaired. These defects recapitulated the Fnip1−/− animal model. Moreover, we identified either uniparental disomy or copy-number variants (CNVs) in 2 patients, expanding the variant spectrum of this novel inborn error of immunity. The results indicate that FNIP1 deficiency can be caused by complex genetic mechanisms and support the clinical utility of exome sequencing and CNV analysis in patients with broad phenotypes, including agammaglobulinemia and HCM. FNIP1 deficiency is a novel inborn error of immunity characterized by early and severe B-cell development defect, agammaglobulinemia, variable neutropenia, and HCM. Our findings elucidate a functional and relevant role of FNIP1 in B-cell development and metabolism and potentially neutrophil activity.

1 January 2014 in Heart Failure Clinics
Verified
Journal Article
Closed access
FRFred H. Rodriguez
Fred H. Rodriguez
AMAriane J. Marelli
Ariane J. Marelli

8 May 2019 in Congenital Heart Disease
Verified
Journal Article
Closed access
PDF file
JGJennifer Gerardin
Jennifer Gerardin
CRCheryl Raskind‐Hood
Cheryl Raskind‐Hood
FRFred H. Rodriguez
Fred H. Rodriguez
THTrenton Hoffman
Trenton Hoffman
AKAndreas Kalogeropoulos
Andreas Kalogeropoulos
WBWendy Book
Wendy Book
Objective Transfer of congenital heart disease care from the pediatric to adult setting has been identified as a priority and is associated with better outcomes. Our objective is to determine what percentage of patients with congenital heart disease transferred to adult congenital cardiac care. Design A retrospective cohort study. Setting Referrals to a tertiary referral center for adult congenital heart disease patients from its pediatric referral base. Patients This resulted in 1514 patients age 16‐30, seen at least once in three pediatric Georgia health care systems during 2008‐2010. Interventions We analyzed for protective factors associated with age‐appropriate care, including distance from referral center, age, timing of transfer, gender, severity of adult congenital heart disease, and comorbidities. Outcome Measures We analyzed initial care by age among patients under pediatric care from 2008 to 2010 and if patients under pediatric care subsequently transferred to an adult congenital cardiologist in this separate pediatric and adult health system during 2008‐2015. Results Among 1514 initial patients (39% severe complexity), 24% were beyond the recommended transfer age of 21 years. Overall, only 12.1% transferred care to the referral affiliated adult hospital. 90% of these adults that successfully transferred were seen by an adult congenital cardiologist, with an average of 33.9 months between last pediatric visit and first adult visit. Distance to referral center contributed to delayed transfer to adult care. Those with severe congenital heart disease were more likely to transfer (18.7% vs 6.2% for not severe). Conclusion Patients with severe disease are more likely to transfer to adult congenital heart disease care than nonsevere disease. Most congenital heart disease patients do not transfer to adult congenital cardiology care with distance to referral center being a contributing factor. Both pediatric and adult care providers need to understand and address barriers in order to improve successful transfer.